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reflect the different turnover of tissues in OA and RA,
and may be a useful tool to evaluate arthritis.
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Bath Ankylosing Spondylitis Functional Index
S i r —As discussed elsewhere [1], we have recently de­
veloped a new method for assessing functional status in 
patients with ankylosing spondylitis (AS): the Bath 
Ankylosing Spondylitis Functional Index (BASFI).
self-assessment instrument was designed by a 
multidisciplinary team of health professionals in con­
junction with patients. In the process of its validation, 
it was compared to the Dougados functional index (FI) 
[2], A recent article in the Journal [3] compared a new
Dutch FI with that of Dougados. We suggest that the 
BASFI has advantages over both.
A number of the limitations of the Dougados FI also 
apply to the Dutch FI. For example, the scoring system 
results from only three possible answers to each of the 
questions in both indices. This renders the instruments 
relatively insensitive to change and also limits use of the 
whole scale. There was no input from physiotherapists 
or patients during the design of the Dougados index 
which resulted in certain 
ambiguously. Initially, we
worded
Dougados
instrument should be simplified and redundant ques 
tions discarded. The BASFI consists of ten particularly 
relevant functions, some from the Dougados FI. The 
ten questions are specific in their instruction, clinically 
relevant, encompass the appropriate anatomy and 
reflect the overall level of function of the patient. The 
use of 10 cm visual analogue scales (VAS) improves 
sensitivity and increases the capacity of the index to 
make use of the whole 0-10 scale: specifically [1], in 
comparison to the Dougados FI, BASFI was more 
sensitive (i.e. there was a 20% improvement to the 
function of 47 consecutive inpatients during a 3-week 
intensive physiotherapy programme, according to 
BASFI, but only a 10% improvement with the Dougados 
scale). Moreover, the scores were distributed across a 
higher proportion of the scale (95 vs 65%, respectively).
The Dutch FI is actually an extended version of 
the Dougados FI. We found [1] internal redundancy 
between some components of the Dougados FI which 
makes it likely that there is yet further internal redund­
ancy within the Dutch FI. In addition, the Dutch index 
takes an average of 5 min for the patients to complete, 
compared to an average of 100 s for BASFI. The Dutch 
FI ranges from 0- 4. However, only 6.1% of the range 
was utilized by their patients’ scores (i.e. 0 2.45). By 
contrast, no less than 95%> of our BASFI scale was 
used (0-9.5 out of 10). That the Dutch authors claim 
good reproducibility no doubt relates to its relatively 
poor sensitivity in recognizing change; BASFI demon­
strates more subtle changes in functional ability due to 
the use of VAS.
The Dutch group conclude that ‘the Dutch FI is a 
potentially useful instrument, which is valid, reliable 
and sensitive to the effects of NSAID treatment, is easy 
to administer and requires little time for 
We suggest that the BASFI, whilst also being valid and 
reliable, is more sensitive to change, easier to adminis­
ter and requires substantially less time for completion 
than the Dutch FI. It could quite simply be translated 
into Dutch, or indeed any other language, as has been 
done with Urdu, Spanish and Portuguese (unpublished 
data).
Perhaps the most significant advantage of BASFI is
of health professionals and, inthat it satisfies 
addition, has particular clinical relevance since patients 
with AS were involved in its design and development. 
Taking into consideration the recent acceptance that 
the patient’s perception of disease is particularly rel­
evant in AS [4], the BASFI and the BASDAI (Bath 
Ankylosing Spondylitis Disease Activity Index, a newly
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developed self-administered instrument to measure dis­
ease activity, [5]) together, provide the best method of 
obtaining accurate data regarding disease progression 
in patients with AS.
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REPLY
Sir—We read with interest the letter by Calin et al, 
regarding our recently published paper. We would like 
to offer the following reply.
We agree with Calin et al. that the functional 
index (FI) of Dougados has some limitations, this was 
mentioned in our introduction and was one of the 
reasons for developing a Dutch version of the FI [1-3]. 
For the development of the Dutch FI we modified the 
Dougados FI extensively. Although all items of the 
Dougados FI were used, additional items have been 
formulated out of interviews with patients with 
ankylosing spondylitis (AS), physical therapists, 
occupational therapists, nurses and psychologists 
professionals familiar with the problems
-all 
to
AS. This resulted in 15 additional items, covering the 
whole field of problems of AS in daily life. At the end 
three items were excluded resulting in an increase in 
Cronbach’s a to 0.94 indicating a reduction of the 
internal redundancy [4].
We have shown a significant change (P <  0.02) with 
the Dutch FI in a 48-week clinical non-steroidal study 
of 55 patients. As a comparison between the Dutch FI 
and the Bath Ankylosing Spondylitis Functional Index 
(BASFI) has not been performed we cannot comment 
on the difference in sensitivity to change between these 
two instruments.
In our study 61 % of the range of the FI was utilized 
compared to 95% in the study of the BASFI [5]. This 
difference can easily be explained by the difference in 
disease duration (10 yr in our study vs 24.7 yr in the
BASFI study) as functional status is correlated with
disease duration.
Both the Dutch version of the FI and the BASFI 
are self-administered and thus simpler to assess than 
the Dougados FI, which is an investigator-assessed
questionnaire.
It would be a good idea to compare and evaluate 
the two questionnaires in a clinical study. However, 
before doing so the BASFI should not only be simply 
translated into Dutch as suggested by Calin et al. but 
also properly validated as the properties of the scale 
might change by using the instrument in another 
population.
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A New Case of Polyarthritis as a Presenting
Sign of Non-Hodgkin’s Lymphoma
Sir—The interesting article by McDonagh et al. [1] 
‘Non-Hodgkin’s lymphoma presenting as polyarthritis’ 
presented three cases of polyarthritis as an initial sign 
of non-Hodgkin’s lymphoma (NHL). In their review of 
the literature, they found that including these three 
cases, only 10 cases of N H L presented as polyarthritis 
have been reported. Three of these 10 cases were 
cutaneous lymphomas with a fourth one arising in an 
angioimmunoblastic lymphadenopathy (AIL). We are 
submitting another case of a patient consulting because 
of polyarthritis and fever, and finally diagnosed with 
NHL.
A 71-yr-old Caucasian female was admitted to our 
hospital with a 15 day history of fever, pruriginous 
rash, pain and swelling in several joints, and malaise. 
Her condition did not improve after treatment with 
penicillin and clavulanate. Physical examination re­
vealed a painless, mobile, rubbery lymph node in 
the right cervical region, a symmetrical polyarthritis 
involving knees, ankles, wrists, metacarpophalangeal 
and proximal interphalangeal joints; and painful 
pharyngeal ulcers that prevented normal swallowing. 
Laboratory data included normochromic normocytic 
anaemia with a haemoglobin of 9.4 g/dl, WBC 
3.7 x 1071, and normal platelet count. Erythrocyte
